Corcept Therapeutics inc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Corcept Therapeutics inc - overview
Established
1998
Location
Menlo Park, CA, US
Primary Industry
Pharmaceuticals
About
Based in California, US, and founded in 1998 by co-founder Joseph Belanoff, MD, Corcept Therapeutics inc operates as a provider of cortisol modulation treatments to medical professionals for treating severe endocrine, oncological, metabolic, and neurological disorders. In April 2012, Corcept Therapeutics raised USD 0. 52 million from unspecified investors. The firm trades on the Nasdaq Stock Exchange under the ticker symbol CORT.
The company provides a wide range of biotechnology products, such as cortisol modulators, including FDA-approved Korlym (mifepristone) for hypercortisolism (Cushing syndrome). Additionally, the firm also provides support services such as patient advocacy and financial assistance programs.
Current Investors
Alta Partners, Sutter Hill Ventures, Paperboy Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.corcept.com/
Total Amount Raised
Subscriber access only
Corcept Therapeutics inc - timeline of key events
Corcept Therapeutics inc - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 3,307,000 | 10,357,000 | 26,551,000 | 50,286,000 | 81,321,000 | 159,201,000 | 251,247,000 | 306,486,000 | 353,874,000 | 365,978,000 | 401,858,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | 213.2% | 156.4% | 89.4% | 61.7% | 95.8% | 57.8% | 22.0% | 15.5% | 3.4% | 9.8% | - | - | - |
| EBITDA (USD) | (32,329,000) | (36,228,000) | (41,387,000) | (27,449,000) | (3,266,000) | 10,287,000 | 52,975,000 | 89,732,000 | 113,777,000 | 131,742,000 | 132,627,000 | 116,986,000 | - | - | - |
| Operating Income (USD) | (32,332,000) | (36,272,000) | (41,496,000) | (27,619,000) | (3,443,000) | 10,179,000 | 52,855,000 | 89,496,000 | 111,606,000 | 128,202,000 | 124,477,000 | 112,634,000 | - | - | - |
| Operating Margin | - | (1096.8%) | (400.7%) | (104.0%) | (6.8%) | 12.5% | 33.2% | 35.6% | 36.4% | 36.2% | 34.0% | 28.0% | - | - | - |
| % EBITDA Margin | - | (1095.5%) | (399.6%) | (103.4%) | (6.5%) | 12.6% | 33.3% | 35.7% | 37.1% | 37.2% | 36.2% | 29.1% | - | - | - |
| NET Income (USD) | (32,354,000) | (38,048,000) | (46,011,000) | (31,383,000) | (6,408,000) | 8,140,000 | 129,122,000 | 75,410,000 | 94,181,000 | 106,011,000 | 112,512,000 | 101,418,000 | - | - | - |
| % Net Margin | - | (1150.5%) | (444.3%) | (118.2%) | (12.7%) | 10.0% | 81.1% | 30.0% | 30.7% | 30.0% | 30.7% | 25.2% | - | - | - |
Corcept Therapeutics inc - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.